Medication check drug information
Metformin AL 1000 tablets
Preparation:
Metformin AL 1000 tablets
Pharmaceutical form:
Tablets
Delivery form:
only available on prescription
Payment Exempt pack sizes:
no
Active Ingredients:
Metformin HCl
About auxiliaries, smell, taste, preservatives and dyes please refer to the leaflet or ask your pharmacist.
We make the package inserts for you to understand: information on side effects, dosage and risks
The following information refers to the / to the active ingredient (s). Please note that this information may differ to the active ingredients of the information in the package insert. To partially different application areas declared by the pharmaceutical manufacturers.
1 What is "metformin tablets AL 1000" and what is it used for?
1.1 What properties does the drug?
"Metformin tablets AL 1000" contains the active ingredient metformin, a drug from the group of so-called oral hypoglycemic agents and biguanides.
Metformin has hypoglycemic properties. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia (low blood sugar).
Metformin is usually applied in the form of metformin hydrochloride salt.
Metformin is a prescription and should only be used on medical advice.
1.2 What are the strengths and dosage forms are there?
Metformin are commonly referred to as
_ Tablets or tablets containing 500 mg, 850 mg or 1000 mg of metformin hydrochloride.
- Oral solution containing 100 mg of metformin hydrochloride in 1 ml
Your doctor determines which potency and dosage are appropriate for your treatment.
1.3 Metformin is used
Sunday, 14 July 2013
The substance of the biguanide like metformin
The substance of the biguanide (metformin)
Metformin belongs to the biguanide derivatives and is the only representative of this class of substance use in the current diabetes therapy. Metformin is a synthetic compound with hypoglycemic effect.
Mode of action of metformin
Metformin has several targets that are important for effective blood sugar. Metformin delayed glucose uptake in the intestinal cell and reduces the release of glucose from the liver. The latter leads to an inhibition of the increase in fasting blood glucose. The effect of insulin is enhanced, leading to an increase in glucose uptake and consumption by muscle and fat cells.
Thus, the fasting blood glucose level is reduced on average by 25 percent without hypoglycemia are generated. The HbA1c value indicating the level of blood sugar over the past two to three months can be reduced with metformin on average by 1.5 percent.
Metformin belongs to the biguanide derivatives and is the only representative of this class of substance use in the current diabetes therapy. Metformin is a synthetic compound with hypoglycemic effect.
Mode of action of metformin
Metformin has several targets that are important for effective blood sugar. Metformin delayed glucose uptake in the intestinal cell and reduces the release of glucose from the liver. The latter leads to an inhibition of the increase in fasting blood glucose. The effect of insulin is enhanced, leading to an increase in glucose uptake and consumption by muscle and fat cells.
Thus, the fasting blood glucose level is reduced on average by 25 percent without hypoglycemia are generated. The HbA1c value indicating the level of blood sugar over the past two to three months can be reduced with metformin on average by 1.5 percent.
Metformin and dapagliflozin decisions on diabetes drugs
Stop G-BA decision on dapagliflozin: DDG
The German Diabetes Society (DDG) appealed in a statement to the Federal Ministry of Health, the decision of the Joint Federal Committee (G-BA) to complain against the diabetes drug dapagliflozin.
The G-BA had its first approved drug from the group of SGLT-2 (sodium-glucose linked Transportation2) inhibitors on 6 June 2013 an additional therapeutic benefit denied. SGLT-2 inhibitors reduce blood sugar by sugar excretion in the urine. But studies show that among dapagliflozin less severe hypoglycaemia occur as in therapy with sulfonylureas.
The German Diabetes Society (DDG) appealed in a statement to the Federal Ministry of Health, the decision of the Joint Federal Committee (G-BA) to complain against the diabetes drug dapagliflozin.
The G-BA had its first approved drug from the group of SGLT-2 (sodium-glucose linked Transportation2) inhibitors on 6 June 2013 an additional therapeutic benefit denied. SGLT-2 inhibitors reduce blood sugar by sugar excretion in the urine. But studies show that among dapagliflozin less severe hypoglycaemia occur as in therapy with sulfonylureas.
Advantage for diabetes medicines like metformin with active ingredient sitagliptin
Press Release: Institute for Quality and Efficiency in Health Care (IQWiG)
In its first evaluation of the existing market IQWiG sees evidence of additional benefits
No meaningful data for other Gliptine
In the free combination of sitagliptin with metformin, there is evidence for a small additional benefit compared to sulfonylureas, where near-normal blood sugar levels are the goal of therapy. Compared to the non-approved in Germany sulfonylurea glipizide, the additional benefit in men is quite substantially. For other substances from the group of Gliptine an additional benefit, however, is not used. To this result, the Institute comes to quality and Efficiency in Health Care (IQWiG), which at first July 2013, the first dossier evaluations of drug market Restructuring Act (AMNOG) has presented for the so-called stock market. Were the subject of active substances from the group of Gliptine.
Major order package to Gliptinen
To the test came three drugs, either as single agent or as a fixed combination with metformin vildagliptin and vildagliptin / metformin, sitagliptin and sitagliptin / metformin and saxagliptin. This had been approved in Germany to treat people with type 2 diabetes mellitus respectively between 2007 and 2009. You are eligible if those concerned with diet and exercise alone can not lower their blood sugar enough or can not tolerate other oral antidiabetic agents.
In its first evaluation of the existing market IQWiG sees evidence of additional benefits
No meaningful data for other Gliptine
In the free combination of sitagliptin with metformin, there is evidence for a small additional benefit compared to sulfonylureas, where near-normal blood sugar levels are the goal of therapy. Compared to the non-approved in Germany sulfonylurea glipizide, the additional benefit in men is quite substantially. For other substances from the group of Gliptine an additional benefit, however, is not used. To this result, the Institute comes to quality and Efficiency in Health Care (IQWiG), which at first July 2013, the first dossier evaluations of drug market Restructuring Act (AMNOG) has presented for the so-called stock market. Were the subject of active substances from the group of Gliptine.
Major order package to Gliptinen
To the test came three drugs, either as single agent or as a fixed combination with metformin vildagliptin and vildagliptin / metformin, sitagliptin and sitagliptin / metformin and saxagliptin. This had been approved in Germany to treat people with type 2 diabetes mellitus respectively between 2007 and 2009. You are eligible if those concerned with diet and exercise alone can not lower their blood sugar enough or can not tolerate other oral antidiabetic agents.
Benefits from Metformin, sitagliptin and Gliptinen
Advantage for sitagliptin
In a first benefit assessment in the stock market after AMNOG rules IQWiG has reduced for the group of DPP-4 inhibitors mainly the thumb. Only for sitagliptin sees indications of an additional benefit. Now the ball is in the GBA, which decides on the added value.
IQWiG recognizes in Gliptinen on
When standard therapy target near normal blood glucose lowering sitagliptin has an advantage.
COLOGNE. According to an order of the JCC, IQWiG has evaluated the group of DPP-4 inhibitors on their added value in recent months, either as a single agent or as a fixed combination with metformin vildagliptin and vildagliptin / metformin, sitagliptin and sitagliptin / metformin and saxagliptin.
These medicines were registered between 2007 and 2009.
In a first benefit assessment in the stock market after AMNOG rules IQWiG has reduced for the group of DPP-4 inhibitors mainly the thumb. Only for sitagliptin sees indications of an additional benefit. Now the ball is in the GBA, which decides on the added value.
IQWiG recognizes in Gliptinen on
When standard therapy target near normal blood glucose lowering sitagliptin has an advantage.
COLOGNE. According to an order of the JCC, IQWiG has evaluated the group of DPP-4 inhibitors on their added value in recent months, either as a single agent or as a fixed combination with metformin vildagliptin and vildagliptin / metformin, sitagliptin and sitagliptin / metformin and saxagliptin.
These medicines were registered between 2007 and 2009.
Subscribe to:
Posts (Atom)